Review
Oncology
Morena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Fernando Paragliola, Francesca Sparano, Maria Lucia Iacovino, Anna Castrichino, Francesca Doria, Antonello Sica, Floriana Morgillo, Giuseppe Colella, Giampaolo Tartaro, Salvatore Cappabianca, Domenico Testa, Gaetano Motta, Fortunato Ciardiello
Summary: Head and neck cancers are the seventh most common cancer worldwide, with squamous cell carcinomas being the most frequent histologic subtype. The current standard treatment includes surgery or radiotherapy for early stage diseases, while locally advanced cases may require a more aggressive multi-modal approach. Anti-EGFR targeted therapy cetuximab is currently the only approved targeted therapy option, with the recent development of immune-checkpoint inhibitors providing new treatment options.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Oncology
Lihua Shu, Dongsheng Wang, Sreenivas Nannapaneni, Youzhi Sun, Christopher C. Griffith, Xu Wang, Zhengjia Chen, Mihir Patel, Mark El-Deiry, Dong M. Shin, Zhuo G. Chen, Nabil F. Saba
Summary: The study tested the potential ability of tipifarnib to impair proliferation in wild-type H-Ras HNSCC. The results showed that tipifarnib has limited ability to slow tumor growth as a single agent, but the combination with cetuximab enhanced its effects, warranting further research.
Editorial Material
Oncology
Hannah Zaryouh, Jinthe Van Loenhout, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters
Summary: Resistance to EGFR-targeted therapy in head and neck cancers is partially mediated by aberrant signaling of the PI3K/Akt pathway. Further research is needed to explore the potential of therapy-induced autophagy as an anti-tumor mechanism and to develop novel therapeutic strategies targeting both the EGFR and PI3K/Akt pathway.
Article
Oncology
Markus Hecht, Dennis Hahn, Philipp Wolber, Matthias G. Hautmann, Dietmar Reichert, Steffi Weniger, Claus Belk, Tobias Bergmann, Thomas Goehler, Manfred Welslau, Christina Gross-Thie, Orlando Guntinas-Lichius, Jens von der Gruen, Panagiotis Balermpas, Katrin Orlowski, Diethelm Messinger, Karsten G. Stenzel, Rainer Fietkau
Summary: In locally recurrent head and neck squamous cell cancer (HNSCC) patients, radiotherapy combined with cetuximab showed better survival outcomes compared to chemotherapy combined with cetuximab.
Review
Chemistry, Medicinal
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Marc Peeters, Jan Baptist Vermorken, Filip Lardon, An Wouters
Summary: Resistance to therapies targeting EGFR in HNSCC is a major challenge, with redundant activation of the PI3K/Akt pathway proposed as a key driver of resistance. Understanding the role of key proteins in this pathway is crucial for developing effective combination strategies. Studies on PI3K/Akt pathway inhibitors show promise in overcoming this resistance and improving clinical efficacy by co-targeting EGFR and PI3K/Akt pathways.
MEDICINAL RESEARCH REVIEWS
(2022)
Article
Otorhinolaryngology
Shuo Yang, Zhi-Jun Yuan, Yue-Hong Zhu, Xue Chen, Wei Wang
Summary: The study revealed that lncRNA PVT1 decreases the sensitivity of HNSCC cells to cetuximab by enhancing methylation-mediated inhibition of miR-124-3p, providing a new insight into the cetuximab chemoresistance of HNSCC.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Oncology
K. Klinghammer, J. Fayette, A. Kawecki, A. Dietz, P. Schafhausen, G. Folprecht, S. Rottey, P. Debourdeau, J. Lavernia, A. Jacobs, I. Ahrens-Fath, B. Dietrich, H. Baumeister, A. Zurlo, S. Ochsenreither, U. Keilholz
Summary: The RESGEX study compared the efficacy and safety of tomuzotuximab and cetuximab with chemotherapy in head and neck squamous cell cancer patients. However, the results did not show a significant difference in progression-free survival or overall survival between the two groups, suggesting that tomuzotuximab did not improve outcomes in this setting.
Article
Oncology
Christine H. Chung, Marcelo Bonomi, Conor E. Steuer, Jiannong Li, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Feifei Song, Juan C. Hernandez-Prera, Bruce M. Wenig, Helen Molina, Joaquim M. Farinhas, Caitlin P. McMullen, J. Trad Wadsworth, Krupal B. Patel, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Nabil F. Saba
Summary: The combination of cetuximab and nivolumab was well tolerated in patients with incurable head and neck squamous cell carcinoma. While patients without prior immune checkpoint inhibitor exposure showed a trend for more favorable progression-free survival, the improvement in 1-year overall survival did not reach statistical significance in this heavily treated patient population. Optimal sequencing of cetuximab and checkpoint inhibitors may impact prognosis and requires further evaluation.
Article
Biochemical Research Methods
Xiaofeng Zhang, Yue Chen, Sung Yun Jung, Xianju Li, Fanjie Meng, Bowen Zhong, Jun Qin, Yi Wang
Summary: In this study, the dynamic interaction network of EGFR wildtype and mutant NSCLC cell lines was characterized. It was found that while the core signaling modules and downstream pathways were maintained in the mutant cell line, receptor internalization and intracellular trafficking were delayed. Additionally, mutant EGFR-associated proteins that could affect EGFR functions in lung adenocarcinoma were identified.
JOURNAL OF PROTEOMICS
(2022)
Article
Biochemistry & Molecular Biology
Peng Liu, Fuqiang Zu, Hui Chen, Xiaoli Yin, Xiaodong Tan
Summary: This study revealed that exosomal DNAJB11 promotes cell development in pancreatic cancer cells by regulating the expression of HSPA5 and activating the endoplasmic reticulum stress pathway. Additionally, exosomal DNAJB11 can regulate the expression of EGFR and activate the MAPK signaling pathway. Clinical studies suggest that exosomal DNAJB11 has the potential to serve as a diagnostic biomarker and therapeutic target for pancreatic cancer.
CELLULAR & MOLECULAR BIOLOGY LETTERS
(2022)
Article
Oncology
Jean-Baptiste Guy, Sophie Espenel, Safa Louati, Arnaud Gauthier, Max-Adrien Garcia, Nicolas Vial, Celine Malesys, Dominique Ardail, Gersende Alphonse, Anne-Sophie Wozny, Claire Rodriguez-Lafrasse, Nicolas Magne
Summary: The combination therapy of ABT-199, cetuximab, and radiation showed promising results in inhibiting the proliferation, invasion, migration, and resistance to apoptosis in both non-CSC and CSC subpopulations of HNSCC, suggesting a potential new treatment strategy for locally advanced HNSCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Summary: This study investigates the dynamic changes in circulating tumor DNA (ctDNA) as an early indicator of treatment outcome. The results show that complete clearance of mutant EGFR ctDNA at 8 weeks is highly and significantly predictive of decreased risk of progression and death in patients with EGFR mutation tissue-positive non-small cell lung cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Hendrik Eggers, Lea Haebel, Arnold Ganser, Viktor Gruenwald, Roland Merten, Athanasia Warnecke, Martin Durisin, Philipp Ivanyi
Summary: The application of cetuximab in palliative first-line therapy for R/M HNSCC patients can significantly improve overall survival, according to the study.
CANCER INVESTIGATION
(2023)
Article
Dentistry, Oral Surgery & Medicine
Caihua Zhang, Zhi Chen, Nailin Gao, Gan Xiong, Peng Chen, Hui Li, Demeng Chen, Qianting He, Liang Peng
Summary: In this study, resistant Bmi1-expressing cells were found during cetuximab treatment, and a novel role of SOX18 in promoting cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) was reported. The study aimed to investigate the regulatory mechanism of Sox18 in Bmi1-positive cells and to search for better therapeutic targets.
Article
Oncology
Dongsheng Wang, Yue Lu, Sreenivas Nannapaneni, Christopher C. Griffith, Conor Steuer, Guoqing Qian, Xu Wang, Zhengjia Chen, Mihir Patel, Mark El-Deiry, Dong M. Shin, Xia He, Zhuo G. Chen, Nabil F. Saba
Summary: Combination therapy targeting EGFR, HER2, and c-Met was found to be more effective in inhibiting SCCHN cell growth and inducing apoptosis compared to single agent therapy. The combinations also demonstrated superior efficacy in tumor growth inhibition in PDX models. These findings support further clinical investigation of such combinations in SCCHN.
Article
Oncology
Solange Peters, Rolf A. Stahel, Urania Dafni, Santiago Ponce Aix, Bartomeu Massuti, Oliver Gautschi, Linda Coate, Ana Lopez Martin, Robbert van Heemst, Thierry Berghmans, Peter Meldgaard, Manuel Cobo Dols, Javier Garde Noguera, Alessandra Curioni-Fontecedro, Daniel Rauch, Michael T. Mark, Sinead Cuffe, Bonne Biesma, Arjen M. J. van Henten, Oscar Juan Vidal, Ramon Palmer Sanchez, Jose Carlos Villa Guzman, Ricardo Collado Martin, Sergio Peralta, Amelia Insa, Yvonne Summers, Istvan Lang, Anne Horgan, Fortunato Ciardiello, Sander de Hosson, Remge Pieterman, Harry J. M. Groen, Paul M. van den Berg, Christoph C. Zielinski, Yojena Chittazhathu Kurian Kuruvilla, Adriana Gasca-Ruchti, Marie Kassapian, Silvia Novell, Valter Torri, Zoi Tsourti, Vanesa Gregorc, Egbert F. Smit
JOURNAL OF THORACIC ONCOLOGY
(2017)
Article
Oncology
T. Moran, J. Wei, M. Cobo, X. Qian, M. Domine, Z. Zou, I. Bover, L. Wang, M. Provencio, L. Yu, I. Chaib, C. You, B. Massuti, Y. Song, A. Vergnenegre, H. Lu, G. Lopez-Vivanco, W. Hu, G. Robinet, J. Yan, A. Insa, X. Xu, M. Majem, X. Chen, R. de las Penas, N. Karachaliou, M. A. Sala, Q. Wu, D. Isla, Y. Zhou, N. Baize, F. Zhang, J. Garde, P. Germonpre, S. Rauh, H. ALHusaini, M. Sanchez-Ronco, A. Drozdowskyj, J. J. Sanchez, C. Camps, B. Liu, R. Rosell
ANNALS OF ONCOLOGY
(2014)
Article
Oncology
R. Salazar, H. Cortes-Funes, E. Casado, B. Pardo, A. Lopez-Martin, C. Cuadra, J. Tabernero, C. Coronado, M. Garcia, A. Soto Matos-Pita, B. Miguel-Lillo, M. Cullell-Young, J. L. Iglesias Dios, L. Paz-Ares
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2013)
Article
Oncology
Beatriz Pardo, Luis Paz-Ares, Josep Tabernero, Eva Ciruelos, Margarita Garcia, Ramon Salazar, Ana Lopez, Maria Blanco, Antonio Nieto, Jose Jimeno, Miguel Angel Izquierdo, Jose Manuel Trigo
CLINICAL CANCER RESEARCH
(2008)
Article
Oncology
Atocha Romero, Eloisa Jantus-Lewintre, Beatriz Garcia-Pelaez, Ana Royuela, Amelia Insa, Patricia Cruz, Ana Collazo, Javier Perez Altozano, Oscar Juan Vidal, Pilar Diz, Manuel Cobo, Berta Hernandez, Sergio Vazquez Estevez, Gretel Benitez, Maria Guirado, Margarita Majem, Reyes Bernabe, Ana Laura Ortega, Ana Blasco, Joaquim Bosch-Barrera, Jose M. Jurado, Jorge Garcia Gonzalez, Santiago Viteri, Carlos Garcia Giron, Bartomeu Massuti, Ana Lopez Martin, Alejandro Rodriguez-Festa, Silvia Calabuig-Farinas, Miguel Angel Molina-Vila, Mariano Provencio
Summary: Various noninvasive EGFR testing platforms have been compared in this study, with NGS platforms and high-sensitivity PCR methods showing good agreement for EGFR sensitizing mutations and T790M testing. Discordant results were mostly observed in samples with mutant allele frequencies <= 0.5%. The study supports the use of liquid biopsies for noninvasive EGFR testing and emphasizes the importance of systematically reporting mutant allele frequencies.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Mariano Provencio, Jose Maria Mazarico Gallego, Antonio Calles, Monica Antonanzas, Cristina Pangua, Xabier Mielgo Rubio, Ernest Nadal, Rafael Lopez Castro, Ana Lopez-Martin, Edel Del Barco, Manuel Domine, Fernando Franco, Pilar Diz, Carmen Sandoval, Elia Sais Girona, Ivana Sullivan, M. Angeles Sala, Gema Garcia Ledo, Marc Cucurull, Joaquin Mosquera, Mireia Martinez, Luis Enrique Chara, Edurne Arriola, Beatriz Esteban Herrera, Jose Ramon Jarabo, Rosa Alvarez Alvarez, Javier Baena, Maria Gonzalez Cao
Summary: The study analyzed the clinical characteristics and outcomes of 447 lung cancer patients with COVID-19, and found that patients with advanced disease and those treated with corticosteroids during hospitalization had a higher mortality rate. Severity of COVID-19 was correlated with increased mortality, ICU admission, and mechanical ventilation rates.
Article
Medicine, Research & Experimental
Silvia Pena-Cabia, Ana Royuela Vicente, Ruth Ramos Diaz, Fernando Gutierrez Nicolas, Angela Penalver Vera, Isabel Siso Garcia, Ricardo Hitt Sabag, Concepcion Garcia Lacalle, Ana Pena-Cabia, Irene Iglesias-Peinado, Benito Garcia Diaz, Ana Lopez-Martin
Summary: Limited literature is available on the exposure-response relationship of bevacizumab, and no concentration threshold is associated with optimal disease control. This real-life observational study aimed to evaluate the relationship between bevacizumab concentrations at steady state and disease control in patients with metastatic colorectal cancer. While no positive association was found with clinical benefit, a higher median Ctrough, SS was associated with better overall survival. More controlled randomized studies are needed to confirm these findings.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Maria Sereno, Ana Maria Jimenez-Gordo, Javier Baena-Espinar, Carlos Aguado, Xabier Mielgo, Ana Pertejo, Rosa Alvarez-Alvarez, Ana Sanchez, Jose Luis Lopez, Raquel Molina, Ana Lopez-Alfonso, Berta Hernandez, Luis Enrique Chiara, Ana Manuela Martin, Ana Lopez-Martin, Miriam Dorta, Ana Collazo-Lorduy, Enrique Casado, Ana Ramirez de Molina, Gonzalo Colmenarejo
Summary: In this study, it was found that the use of G-CSF treatment in neutropenic cancer patients infected with COVID-19 may lead to poor outcomes. The number of days on G-CSF treatment was associated with a higher risk of mortality in these patients.
Article
Oncology
Mariano Provencio, Delvys Rodriguez-Abreu, Ana L. Ortega, Gloria Serrano, Carlos Aguado, Fernando Franco, Vanesa Gutierrez, Guillermo Lopez Vivanco, Maria Guirado, Gretel Benitez, Anna Estival, Virginia Calvo, Beatriz Jimenez, Hugo Arasanz, Juan Coves, Margarita Majem, Bartomeu Massuti, Sergio Vazquez, Oscar Juan-Vidal, Ana Collazo-Lorduy, Clara L. Gozalvez, Edel Del Barco, Adriana Rosero, Joaquim Bosch-Barrerra, Maria A. Moreno, Xavier Mielgo-Rubio, Jose C. Villa, Ana Lopez-Martin, Juan F. Cordoba, Francisco de Asis Aparisi, Marta Zafra, Joaquin Mosquera, Javier Perez Altozano, Ernest Nadal, Silvia Catot, Jose Balsalobre, Teresa de Portugal, Paloma Martin, Susana Cuesta de Juan, Manuel Cobo
Summary: A study conducted in 50 Spanish hospitals showed that approximately 8.5% of lung cancer patients had IgG antibodies against SARS-CoV-2 during the first wave of the pandemic, with most still undergoing cancer treatment. When retested around 4.5 months later, 30.8% of patients did not have detectable IgG antibodies.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Oncology
Guillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodriguez-Vida, Georgia Anguera, Marc Campayo, Alvaro Pinto, Esther Martinez Ortega, Enrique Gallardo, Natalia Fernandez Nunez, Iciar Garcia-Carbonero, Oscar Reig, Maria Jose Mendez-Vidal, Ovidio Fernandez-Calvo, Natalia Vidal Cassinello, Dolores Torregrosa, Ana Lopez-Martin, Adriana Rosero, Patricia G. Valiente, Carmen Garcias de Espana, Miguel A. Climent, Montserrat Domenech Santasusana, Angel Rodriguez Sanchez, Isabel Chirivella Gonzalez, Ruth Afonso, Xavier Garcia del Muro, Javier Casinello, Eva M. Fernandez-Parra, Lourdes Garcia Sanchez, Javier Afonso, Susana Hernando Polo, Ursula Asensio
Summary: This study analyzed the characteristics of patients with complete response to sunitinib and found that a complete response could be achieved regardless of the prognosis group, metastasis site or histology type. 75% of patients remained in complete response after 10 years.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Mariano Provencio, Anna Estival, Fernando Franco, Guillermo Lopez-Vivanco, Maria Saigi, Hugo Arasanz, Pilar Diz, Enric Carcereny, Javier Garcia, Carlos Aguado, Joaquin Mosquera, Eluska Iruarrizaga, Margarita Majem, Joaquim Bosch-Barrera, Xavier Mielgo-Rubio, Maria Guirado, Oscar Juan-Vidal, Ana Blasco, Clara Lucia Goz, Anabel Del Barrio, Teresa De Portugal, Ana Lopez-Martin, Gloria Serrano, Begona Campos, Judit Rubio, Silvia Catot, Beatriz Esteban, Juan Luis Marti-Ciriquian, Edel del Barco
Summary: Lung cancer patients can safely and effectively generate an immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received. The use of immunotherapy or oral targeted therapy and administration of the mRNA-1273 vaccine were associated with an increased likelihood of seropositivity.
Article
Oncology
Margarita Martin, Raul Hernanz, Carmen Vallejo, Leonardo Guerrero, Xabier Mielgo, Ana Lopez, Juan Carlos Trujillo-Reyes, Felipe Counago
Summary: This study aims to elucidate the best therapeutic options for patients diagnosed with brain metastases from NSCLC, including surgery, radiotherapy, radiosurgery, or systemic treatment, as well as the most effective combinations and timings with the lowest associated toxicity.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY
(2022)
Article
Oncology
Ana Lopez-Martin, Claudio Ballestin, Rocio Garcia-Carbonero, Angel Castano, Fernando Lopez-Rios, Angel Lopez-Encuentra, Montserrat Sanchez-Cespedes, Daniel Castellano, Adela Bartolome, Hernan Cortes-Funes, Luis Paz-Ares
Article
Infectious Diseases
A Sánchez-Muñoz, JM Aguado, A López-Martín, F López-Medrano, C Lumbreras, FJ Rodríguez, R Colomer, H Cortés-Funes
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2005)
